Louisiana lawmakers have sent the governor a bill to create a psychedelic-assisted therapy pilot program, using opioid settlement dollars to fund clinical trials aimed at developing alternative treatments such as psilocybin, ibogaine and MDMA.
The Senate signed off the final version of the proposal from Sen. Patrick McMath (R) on Friday in a unanimous 35-0 vote and the House of Representatives’s tally to approve it was 97-0 on Sunday.
The House last month added MDMA to the scope of the original Senate legislation, and also made technical changes to the text. The Senate objected, however, to what supporters said was an error in the revised version, and members requested that the measure be sent to a bicameral conference committee, where that was resolved before the corrected bill came back to the floor of both chambers for final votes.
The psychedelics legislation now heads to the desk of Gov. Jeff Landry (R) for consideration.
Rep. Neil Riser (R), who presented the legislation to the House, said previously that the amendment adding MDMA “put us in positive correlation” with a psychedelics executive order recently signed by President Donald Trump “so that we can look at all different alternatives, including those that are
Read full article on Marijuana Moment
